Amunix is a technology company.
Amunix has raised $193.0M across 2 funding rounds.
Amunix has raised $193.0M in total across 2 funding rounds.
Amunix has raised $193.0M in total across 2 funding rounds.
Amunix's investors include Frazier Healthcare Partners.
Amunix Pharmaceuticals is a biopharmaceutical company developing masked, protease-activated pro-drugs for immuno-oncology, focusing on T-cell engagers (TCEs) and cytokines to treat solid tumors.[1][2][3] It leverages proprietary platforms like Pro-XTEN, XPAT® (for TCEs), and XPAC™ (for cytokines) to create therapeutics that remain inactive until activated in the tumor microenvironment, addressing on-target/off-tumor toxicity and enabling safer, more effective dosing with extended half-life and low immunogenicity.[2][3][4][5] The company serves cancer patients with HER2-expressing solid tumors and others, solving key challenges in potent immune activators that limit efficacy due to systemic toxicity; its lead candidate, AMX-818 (XPAT® TCE), is in IND-enabling studies, with additional programs in optimization.[3][4] Amunix raised $117M in Series B financing in 2024 from Bain Capital Life Sciences and others to advance its oncology pipeline, following technology licensing deals with Roche and prior collaborations with Sanofi and Merck.[4][5][7]
Founded in 2006 in South San Francisco, CA, Amunix initially developed the XTEN® platform—a synthetic, unstructured polypeptide for extending serum half-lives of protein therapeutics with low immunogenicity, validated through partnerships like Merck, Roche, and Sanofi (e.g., in efanesoctocog alfa for hemophilia A).[7][8][5] The idea emerged from needs in protein engineering for longer-acting biologics; early traction came via technology licensing, positioning Amunix as a platform provider.[7][5] Under CEO Angie You, Ph.D., it pivoted around 2021-2024 from pure licensing to internal oncology drug discovery, building a pipeline of Pro-XTEN pro-drugs after Sanofi's failed $1B acquisition attempt in 2021, which highlighted the tech's promise amid toxicity hurdles in immuno-oncology.[6][7][2] This shift capitalized on clinical validation of XTEN and protease-releasable masking for tumor-selective activation.[4][5]
Amunix rides the immuno-oncology wave, targeting bispecific TCEs and cytokines for solid tumors where traditional therapies fail due to toxicity, amid a market shift toward conditionally active biologics.[2][6][7] Timing aligns with post-2021 learnings from cytokine/TCE setbacks (e.g., cytokine release syndrome), as protease-activated pro-drugs gain traction for precision activation.[3][4] Favorable forces include rising demand for safer IO agents, validated half-life extension tech, and partnerships validating XTEN beyond oncology; Amunix influences the ecosystem by licensing platforms, accelerating partner pipelines while building its own, potentially reshaping TCE/cytokine adoption in solid tumors.[5][7]
Amunix is poised to advance AMX-818 into clinical trials post-IND, with XPAC cytokines like IL12 following, fueled by 2024 Series B funding amid a pivot to proprietary oncology assets.[3][4] Trends like AI-driven protein design and tumor-microenvironment targeting will amplify its Pro-XTEN edge, potentially drawing more Big Pharma deals or acquisition interest akin to Sanofi's 2021 bid.[6][7] Its influence may evolve from tech licensor to full-fledged oncology player, delivering breakthrough TCEs/cytokines that unlock solid tumor potential—transforming Amunix from half-life innovator to toxicity conqueror in cancer therapy.[2][5]
Amunix has raised $193.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $120.0M Series B | Frazier Healthcare Partners | |
| Mar 1, 2020 | $73.0M Series A | Frazier Healthcare Partners |